NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2023, Vol. 35 ›› Issue (4): 648-655.doi: 10.16333/j.1001-6880.2023.4.012

Previous Articles     Next Articles

Therapeutic effect and mechanism of cistanche phenylethanoid glycosides on chronic altitude disease model rats

SHULIPAN·Mulati,JIANG Rong-song,ZHANG Wei-yi*,TAO Yi-cun*   

  1. School of Pharmacy,Xinjiang Medical University,Urumqi 830000,China
  • Online:2023-04-24 Published:2023-04-24

Abstract:

To observe the therapeutic effect and mechanism of phenylethanoid glycosides from cistanche (PhGCs) on chronic mountain sickness (CMS) model rats,the red blood corpuscle,hemoglobin,hematocrit value,endothelin-1 (ET-1),and nitric oxide (NO) content,nitric oxide synthase (NOS) enzyme activity,the expression and mRNA levels of peroxisome proliferator-activated receptor alpha(PPAR-α),hypoxia-inducible factor 1(HIF-1α),vascular endothelial growth factor (VEGF) in the homogenate of lung tissue were measured.Results showed that PhGCs and Rhodiola rosea can reduce the right ventricular hypertrophy and the ET-1 content,increase the NO content and the enzyme activity of total nitric oxide synthase (T-NOS),endothelial nitric oxide synthase (eNOS),inducible nitric oxide synthase (iNOS),down-regulate the expression and mRNA levels of HIF-1α and VEGF,up-regulate the expression of PPAR-α in the homogenate of lung tissue of CMS;furthermore,the red blood corpuscle,hemoglobin and hematocrit value had no significant changes compared with rats in model group.In this study,it was confirmed that PhGCs inhibit HIF pathways and activate NO pathways.

Key words: phenylethanoid glycosides from cistanche, chronic mountain sickness, hypoxia-inducible factor pathway

CLC Number: